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Abstract
Background: Airway wall remodelling is an important pathology of asthma. Growth factor induced airway smooth
muscle cell (ASMC) proliferation is thought to be the major cause of airway wall thickening in asthma. Earlier we
reported that Dimethylfumarate (DMF) inhibits platelet-derived growth factor (PDGF)-BB induced mitogen and
stress activated kinase (MSK)-1 and CREB activity as well as IL-6 secretion by ASMC. In addition, DMF altered
intracellular glutathione levels and thereby reduced proliferation of other cell types.
Methods: We investigated the effect of DMF on PDGF-BB induced ASMC proliferation, on mitogen activated
protein kinase (MAPK) activation; and on heme oxygenase (HO)-1 expression. ASMC were pre-incubated for 1 hour
with DMF and/or glutathione ethylester (GSH-OEt), SB203580, hemin, cobalt-protoporphyrin (CoPP), or siRNA
specific to HO-1 before stimulation with PDGF-BB (10 ng/ml).
Results: PDGF-BB induced ASMC proliferation was inhibited in a dose-dependant manner by DMF. PDGF-BB
induced the phosphorylation of ERK1/2 and p38 MAPK, but not of JNK. DMF enhanced the PDGF-BB induced
phosphorylation of p38 MAPK and there by up-regulated the expression of HO-1. HO-1 induction inhibited the
proliferative effect of PDGF-BB. HO-1 expression was reversed by GSH-OEt, or p38 MAPK inhibition, or HO-1 siRNA,
which all reversed the anti-proliferative effect of DMF.
Conclusion: Our data indicate that DMF inhibits ASMC proliferation by reducing the intracellular GSH level with
subsequent activation of p38 MAPK and induction of HO-1. Thus, DMF might reduce ASMC and airway
remodelling processes in asthma.
Background
Asthma is a chronic inflammatory disease of the airways
that is characterised by airway hyper-responsiveness
(AHR), increased broncho-constriction, and an increased
airway wall thickness [1]. The increase of the airway
smooth muscle cell (ASMC) mass in asthma results in
thickening of the airway wall by increasing the mass of
contractile cells and reduction of the bronchial lumen.
Increased levels of platelet-derived growth factor (PDGF)-
BB have been reported in asthma patients’ lung and may
contribute to the increased ASMC mass [2-6].
Inhaled glucocorticoids (GC) remain the most effective
anti-inflammatory therapy in chronic lung diseases [7].
In an earlier study, we and others showed that glucocorti-
coids may have no anti-proliferative effect on ASMC of
asthma patients due to a deficiency in C/EBP-a [8] which
is essential to form a complex with the activated gluco-
corticoid receptor in order to induce p21 [9,10]. In a
recent publication, the lack of the anti-proliferative effect
of glucocorticoids on asthmatic ASMC was confirmed.
Interestingly, vitamin D acted as an anti-proliferative
agent further down-stream of p21
(waf1/cip1), namely on
p53 [11].
Fumaric acid esters (FAE) including dimethylfumarate
(DMF) are registered in Germany for the therapy of
severe psoriasis. Furthermore, the clinical efficacy of
DMF to reduce inflammation in multiples sclerosis has
been demonstrated [12]. Some of psoriasis and multiples
sclerosis patients who also suffered from asthma * Correspondence: rothmic@uhbs.ch
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improved the overall quality of life.
Focusing on the anti-proliferative properties of DMF,
several mechanisms have been described by which DMF
can achieve this effect. In human colon carcinoma cells,
DMF inhibited cell prolifera t i o nb yd o w nr e g u l a t i n g
intracellular GSH levels [13]. Similarly, in human
T-lymphmphocytes, the DMF reduced cell proliferation
was rescued by exogeneous glutathione [14]. Other
in vitro studies showed that DMF down-regulated the
level of cellular glutathione (GSH) in epithelial cells and
asterocytes [15,16]. In human lung fibroblasts, depletion
of GSH up-regulates the enzyme heme oxygenase (HO)-
1 [17]. Interestingly in human ASMC, HO-1 inhibited
cell proliferation [18]. Earlier we have reported that DMF
inhibited PDGF-BB induced MSK-1 and CREB activation,
thereby down-regulating the secretion of IL-6, eotaxin
and RANTES [19]. However, it remains unknown
whether DMF has anti-proliferative properties in ASMC.
In this study we determined the effect of DMF on
PDGF-BB induced ASMC proliferation and HO-1
expression. In addition, we assessed the drugs effect on
intracellular GSH and its role in proliferation control.
Furthermore, we determined the role of JNK, p38, and
ERK1/2 MAPK activation and GSH in DMF induced
HO-1 expression.
Methods
Isolation, characterisation and culture of human ASMC
Human ASMC were isolated and grown from bronchi of
resected unused lung tissue obtained from transplant
donors as previously described [20]. ASMC were grown in
RPMI-1640 (ThermoTrace, Melbourne, Australia) supple-
mented with 5% (v/v) heat-inactivated fetal bovine serum
(FBS), 1× (v/v) MEM vitamin-mix, 100 U/l penicillin,
100 μg/ml streptomycin, and 0.25 μg/ml of amphotericin
B (all: GIBCO/BRL, Melbourne, Australia), 25 mM HEPES
and 2 mM L-glutamine (ThermoTrace) in a humidified
atmosphere at 37°C, in 5% CO2, and 95% air (v/v). All
ASMC lines were used between passages 5-8. ASMC were
characterised by positive immuno-staining for a-SMA and
calponin [20] as shown in Figure 1A.
Drug preparation
DMF (0.1-50 μM), SB203580 (10 μM), Hemin (1-10 μM),
and cobalt-protoporphyrin (2-20 μM) were dissolved in
dimethysulfoxide (DMSO; all Sigma, Buchs, Switzerland)
and diluted to the required concentration in serum free
medium. Glutathione-ethylester (GSH-OEt, 1 mM,
Sigma) was dissolved in serum free medium.
HO-1 suppression by siRNA
HO-1 expression in subconfluent cells was down regu-
lated while the cells where serum deprived for 24 hours
by transfecting the cells with HO-1 siRNA (Santa Cruz
Biotechnology, Santa Cruz, USA: cat# sc-35554) as
described previously (19). After 24 hours cells were
stimulated with PDGF-BB (10 ng/ml) and/or DMF (1 or
10 μM) and proliferation was determined after 72 hours
by direct cell counts.
HO-1 expression and MAPK (p38, JNK, ERK 1/2) activation
ASMC were grown in 6-well plates to confluence and
were then deprived of serum for 24 hours. The cells
were then pre-treated for 1 hour with a single drug, or
with a drug combination, before being stimulated with
PDGF-BB (10 ng/ml). Total cell lysates were collected at
0, 5, 10, 15, 30 or 60 minutes and MAPK expression
and activation was determined by immuno-blot. HO-1
expression was determined at 24 hours.
Immunoblotting
Protein extracts were size-fractionated by SDS-PAGE elec-
trophoresis and transferred onto nitrocellulose membranes
as described previously [19]. Protein transfer was con-
firmed by Ponceau staining. Membranes were incubated
with blocking buffer (5% w/v non-fat dry milk in Tris-
buffered saline containing 0.1% Tween 20) for 1 h at room
temperature and were then incubated with one of the
following primary antibodies: anti-p38, anti-phospho-
p38, anti-ERK1/2, anti-phospho-ERK1/2, anti-JNK, anti-
phospho-JNK (all Cell Signalling Technology, Beverly,
MA), anti-HO-1 (Calbiochem, Luzern, Switzerland) anti-
a-Tubulin (Santa Cruz, Santa Cruz, USA). Primary antibo-
dies were detected by horseradish peroxidase-conjugated
IgG antibodies diluted 1:2000-1:40000 (anti-rabbit IgG
sc-2004, or anti-mouse IgG sc2005; Santa Cruz) and pro-
tein bands were visualised by enhanced chemilumines-
cence (Pierce Biotechnology Inc. Rockford, USA).
ASMC proliferation
Proliferation was measured by [
3H]-thymidine incor-
poration. In brief, ASMC were seeded into 96-well
plates at 60% confluence and serum-deprived for 24
hours. Cells were pre-treated for 1 h with the different
drugs alone or in combination and stimulated with
PDGF-BB (10 ng/ml) for 24 hours. During the final
3h o u r s ,2μCi/ml [
3H]-thymidine (Amersham) were
added and the incorporated [
3H]-thymidine was deter-
mined by liquid scintillation counting [21].
In addition, manual cell counts were performed after
3 days of culture as described earlier using an improved
Neugbaur chamber slide [20]. Subconfluent ASMC were
transfected with HO-1 siRNA as previously described
above and then deprived of serum for 24 hours. ASMC
were then treated with DMF (1, 10 μM) and/or PDGF-
BB (10 ng/ml) and proliferation was determined by
manual cell counts after 72 hours.
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Proliferation data are expressed as mean ± S.E.M. The
statistical analysis was performed using the two-sided
Wilcoxon-Mann-Whitney U-test.
Results and Discussion
In this study we show that DMF inhibits the pro-prolif-
erative action of the asthma relevant growth factor
PDGF-BB on human ASMC via an increase of HO-1.
DMF achieves this effect by depletion of intracellular
GSH which in turn activates p38 MAPK by a yet un-
known mechanism and this increases the expression of
HO-1.
In asthma characteristic structural abnormalities of the
airway wall include an excessive accumulation of ASMC
which express increased levels of connective tissue ele-
ments. Importantly, these pathologies correlated with
severity of the disease and were widely resistant to con-
ventional therapies [22]. Further evidence for the
significant contribution of ASMC to asthma comes from
a novel form of therapy: thermoplasty of ASMC. This
therapy eliminated ASMC by over heating the cells by
means of radio-waves and results in lasting improve-
ment of severe asthma [23]. Besides remodelling, ASMC
actively sustain or increase inflammation in asthma by
secreting a large range of pro-inflammatory cytokines
and various pro-inflammatory components of the extra-
cellular matrix [24,25]. Especially the asthma relevant
growth factor PDGF-BB induced ASMC proliferation, as
well as it activated the cells to secrete components of
the extracellular matrix [25,26]. Thus, reducing the
number of ASMC in asthma may resolve several pathol-
ogies and therefore improve lung function and quality
of life.
In ASMC treated with the vehicle in the presence or
absence of PDGF-BB, we observed no induction of HO-1
expression as shown in a representative immuno-blot in
Figure 1A. In contrast, DMF induced the expression of
Figure 1 DMF induces heme-oxygenase-1 (HO-1) expression and inhibits proliferation in primary ASMC. (A) a representative immuno-blot of
the concentration-dependent effect of DMF on HO-1 expression at 24 h by ASMC. Similar results were obtained in three cell lines. “V” indicates the
drug’s vehicle 0.05% DMSO. (B) DMF inhibited PDGF-BB induced fibroblast proliferation (24 h). Data represents the mean ± SEM of six independent
experiments performed in 3 ASMC lines. Statistics have been calculated by Mann Whitney test. “V” indicates the drug’sv e h i c l e0 . 0 5 %D M S O .
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not altered by the presence of PDGF-BB (Figure 1B). The
PDGF-BB induced the proliferation of ASMC was signifi-
cantly inhibited in a dose-dependent manner by DMF at
concentration >1 μM (Figure 1B).
Together with others our observation suggests that DMF
is a strong inducer of HO-1 in smooth muscle cells, as the
drug inhibited remodelling of pulmonary vessels in rats,
and thus indicates an overall anti-remodelling effect [27].
Furthermore, HO-1 expression reduced hypoxia induced
pulmonary vessel remodelling in rats with chronic pul-
monary heart disease [28]. In order to determine whether
the induction of HO-1 mediates the anti-proliferative
effect of DMF in ASMC, we treated the cells with the
HO-1 inducers hemin (1-10 μM) or cobalt-protoporphyrin
(2-20 μM) 1 hour before stimulation with PDGF-BB.
As depicted in Figure 2, Cobalt-protoporphyrin dose-
dependently reduced PDGF-BB induced ASMC prolifera-
tion. Hemin however, showed such an effect only at the
highest concentration (10 μM) (Figure 2). Neither Cobalt-
protoporphyrin (20 μM) nor hemin (10 μM) had any sig-
nificant effect on ASMC proliferation in un-stimulated
cells (Figure 2). Our finding that other HO-1 inducers
(hemin, CoPP) also inhibit cell proliferation of is in agree-
ment with reports that HO-1 reduced the proliferation of
isolated human lymphocytes [14] and of pancreatic stellate
cells [29].
Furthermore, in line with our results, GSH depletion
was reported to increase the phosphorylation of p38
MAPK in C6 glioma cells [30]. Taken together with
the observation that HO-1 is regulated by p38 MAPK
[29] our data suggest that DMF and GSH reduction
augment HO-1 expression in a p38 MAPK dependent
way. In our experimental conditions PDGF-BB strongly
activated the phosphorylation of ERK 1/2 MAPK
between 5-30 minutes, and DMF had no effect on this
signalling activity (Figure3 A ) .P D G F - B Bi n d u c e dt h e
phosphorylation of p38 MAPK within 5-15 minutes,
declining to baseline levels thereafter (Figure 3B). Sur-
prisingly, the pre-incubation of ASMC with DMF acti-
vated p38 MAPK significantly (Figure 3B, lane 7) and
the combination of PDGF-BB with DMF (50 μM)
further increased and prolonged p38 MAPK activity
(Figure 3B). Neither PDGF-BB, nor DMF alone or in
combination had any effect on the expression of total
p38, or ERK 1/2 MAPK (Figure 3A,B). JNK phosphory-
lation was neither induced by PDGF-BB nor by DMF.
Next we assessed the possible link between DMF
induced activation of p38 MAPK and the induction of
HO-1 expression. As shown in Figure 3C, the p38 MAPK
Figure 2 HO-1 induction inhibits ASMC proliferation. The HO-1 inducer cobalt-protoporphyrin (CoPP) and hemin inhibited PDGF-BB induced
fibroblast proliferation after 24 h. Data represents mean ± SEM of six independent experiments performed in 3 ASMC lines. Statistics have been
calculated by Mann Whitney test. “V” indicates the drug’s vehicle 0.05% DMSO.
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expression of HO-1, whereas SB203580 alone had no
effect on HO-1 level.
A role of oxidative stress, GSH and of its major meta-
bolizing enzyme glutathione-S transferase in asthma has
been proposed [31], but the data was led to controversial
interpretations and the underlying mechanism is not
understood [32,33]. Like other studies, we observed that
the anti-proliferative action of DMF was linked to its
ability to reduce intracellular GSH level [13,15,16]. The
Figure 3 DMF activates phosphorylation of p38 MAP kinase and p38 MAPK inhibition reduces DMF induced HO-1 in ASMC. (A) a
representative immuno-blot of the PDGF-BB induced ERK1/2 MAPK (p-ERK1/2) phosphorylation kinetic in the presence and absence of DMF.
Similar results were obtained in three additional cell lines. (B) a representative immuno-blot of the kinetic of PDGF-BB induced ERK1/2 MAPK (p-
ERK1/2) phosphorylation and its enhancement by DMF; similar results were obtained in three cell lines. (C) a representative immuno-blot of
DMF-induced HO-1 expression and its reduction by the p38 MAPK inhibitor SB203580 Similar results were obtained in three cell lines.
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Page 5 of 8Figure 4 GSH reverses the effects of DMF on p38 MAPK phosphorylation, on HO-1 expression and on ASMC proliferation. (A) a
representative immuno-blots of the reversing effect of GSH on DMF- and PDGF-BB induced of p38 MAPK phosphorylation in ASMC at 30 min.
Similar results were obtained in three cell lines.. (B) a representative immuno-blot of the reversing effect of GSH on the DMF-induced HO-1
expression at 24 h; similar results were obtained in three additional cell lines.. (C) a counteractive effect of GSH on DMF dependent inhibition of
ASMC proliferation. Similar results were obtained in four cell lines. Data represents mean ± SEM (unpaired student’s t-test). “V” indicates the
drug’s vehicle 0.05% DMSO. (D) down regulation of HO-1 by a respective siRNAs counteracted the anti-proliferative effect of DMF. Data
represents the mean ± SEM of 9 independent experiments performed in 3 ASMC lines. Statistics have been calculated by Wilcoxon-Mann-
Whitney U-test.
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of HO-1 by human lung fibroblasts [34], and the deple-
tion of GSH in airway epithelial cells ASMC up-regulated
HO-1 expression [35,36]. These studies support our find-
ing that DMF inhibits ASMC proliferation by depletion
of GSH and up-regulating of HO-1. As shown above,
DMF enhanced PDGF-BB induced p38 MAPK phosphor-
ylation and this effect was completely reversed in the pre-
sence of GSH-OEt (Figure 4A). GSH-OEt itself had no
significant effect on PDGF-BB induced p38 MAPK acti-
vation (Figure 4A). The DMF-induced expression of HO-
1 was completely suppressed in the presence of GSH,
whereas GSH-OEt alone had no effect (Figure 4B).
As shown in figure 4C, neither the drug vehicle
(DMSO) nor DMF alone had significant effects on non-
stimulated ASMC proliferation (bars 1, 2). GSH-OEt
increased proliferation under all conditions, but this
effect did not become significant compared to the
respective controls (bars 3, 4, 8). Most importantly, the
PDGF-BB induced ASMC proliferation (bar 5) was sig-
nificantly inhibited by 1 hour pre-incubation with DMF
(bar 6) and this effect was reversed by the addition of
GSH-OEt (bar 7).
We further investigated the role of HO-1 in DMF
dependent inhibition of cell proliferation by the use of
various concentration of siRNA targeting HO-1 as
shown in figure 4D. HO-1 siRNA alone did not signifi-
cantly change cell proliferation in serum deprived
ASMC over 3 days (Figure 4D). Similarly, the control
siRNA or DMF (10
-6 -1 0
-5M). PDGF-BB dose depen-
dently increased cell numbers by maximal 2.4 folds over
3 days and this effect was dose dependently inhibited by
DMF (Figure 4D). The pre-incubation of ASMC with
HO-1 siRNA, prior to the addition of PDGF-BB and
DMF, counteracted the anti-proliferative effect of DMF
in a clearly dose dependent pattern as shown in figure
4D. This finding supports the hypothesis that HO-1
mediates the anti-proliferative effect of DMF.
Conclusions
In conclusion, our data show that DMF down-regulates
PDGF-BB induced proliferation of ASMC through a
GSH and p38 MAPK dependent induction of HO-1.
The clinical efficacy of DMF and its safety profile in
psoriasis and multiples sclerosis makes it an interesting
drug that may help to reduce airway wall remodelling
and inflammation in chronic inflammatory lung diseases
such as asthma and COPD.
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